Elektrosens
Financiado
Wearable Sweat based painless and continuous glucose monitoring device for diabe...
There are 60 million people with diabetes in the EU (10% of total population). Diabetes is the major cause of death in the age of 20- 79. Also, Europe has the highest number of children with Type 1 diabetes (T1D) compared to other...
There are 60 million people with diabetes in the EU (10% of total population). Diabetes is the major cause of death in the age of 20- 79. Also, Europe has the highest number of children with Type 1 diabetes (T1D) compared to other regions with approximately 140,000 diagnosed children and it has one of the highest prevalence rates of diabetes in children with 21,600 new cases per year. The frequent glucose monitoring is the key element in achieving good glycemic control which is the most important factor in preventing diabetes related complications such as diabetic retinopathy, kidney damage, heart disease, stroke and etc. Due to the high cost of the current CGM devices or pain associated with traditional finger-prick measurement, people cannot monitor their blood glucose level continuously. In 2015, 627,000 people aged between 20-79 died due to diabetes related complications. UK prospective study shows that continuous glucose monitoring leads to improved glycemic control, which in turn results in reduced diabetes related complications. Study shows that with continuous glucose monitoring diabetes related retinopathy and nephropathy (eye damage) in type 1 and type 2 diabetes decreased around 60% and microvascular complication rate decreased 25%.
Elektrosens Wristband uses a highly selective and accurate novel polymer technology sensing very low sweat glucose levels which are correlated to blood glucose. Our innovative solution makes the continuous glucose monitoring affordable for all customer segments. The main objectives of this product can be divided into two groups; mainly providing a sustainable healthy lifestyle and reducing the economic burdens., we now aim to introduce our technology to diabetes devices market seeing how our solution offers significant performance improvements and is market disrupting in its potential. Our new prototype designed and built, is currently at TRL6 stage.
ver más
Duración del proyecto: 4 meses
Fecha Inicio: 2019-12-03
Fecha Fin: 2020-04-30
Fecha Fin: 2020-04-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-04-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
ELEKTROSENS SAGLIK VE DANISMANLIK HIZMETLERI...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
230.34K€ |
Participante